Statistics from Altmetric.com
Randomised (allocation concealed*), unblinded, placebo controlled trial with follow up at age 1 year.
2 neonatal intensive care units (NICUs) in North Carolina, USA.
118 infants (53% boys, 61% white) who were 15–25 days old and had birth weight <1501 g; <10% decrease in ventilator settings for the previous 24 hours and fraction of inspired oxygen (FIO2) ≥0.3; no clinical signs of sepsis; and no echocardiographic evidence of patent ductus arteriosus. 95 infants (81%) survived to 1 year adjusted age; 93 of these surviving infants completed follow up.
57 infants were allocated to dexamethasone, 0.25 mg/kg twice each day for 3 days, then 0.15 mg/kg twice each day for 3 days, then a 10% reduction in dose every 3 days until a 0.1 mg/kg dose was reached on day 34; after 3 days on this dose, 0.1 mg/kg every day until 42 days after study entry. 61 infants were allocated to placebo. Dexamethasone and placebo were given intravenously or enterally.
Main outcome measures
Main outcomes related to initial hospital stay included number of days on assisted ventilation and on supplemental oxygen. At 1 year adjusted age, outcomes included survival, cerebral palsy, and neurological abnormality (cerebral palsy or hypotonia).
Infants who received dexamethasone had fewer days on assisted ventilation (median 13 v 25 d, p=0.005) and fewer days on supplemental oxygen (median 59 v 100 d, p=0.03) than did infants who received placebo. The groups did not differ for survival at 1 year adjusted age (88% v 74%, p=0.07). Surviving infants (n=93) who received dexamethasone were more likely to be diagnosed with possible or definite cerebral palsy or neurological abnormality (table⇓); similar results were obtained after adjusting for major cranial abnormality.
Among very low birth weight infants, a 42 day tapering course of dexamethasone reduced duration of assisted ventilation and time on supplemental oxygen; however, at 1 year adjusted age, infants who had received dexamethasone were more likely to be diagnosed with cerebral palsy and neurological abnormality.
The study reported by Kothadia et al and O'Shea et al is the first large randomised trial to look at both the short term and 1 year outcomes of a 42 day regimen of dexamethasone for the prevention of chronic lung disease in premature infants. The findings of reduced duration of ventilator and oxygen dependency are consistent with those of a similar study1 and those in studies examining shorter regimens.2–3 The finding of an increased risk of cerebral palsy at 1 year adjusted age is supported by Yeh et al.4
One of the strengths of this study is that, unlike other studies, none of the infants in the placebo group was allowed to cross over into the treatment group and receive dexamethasone. Limitations of the study include the sample size of 118, which was the size needed to detect a difference in ventilator dependency. This sample size may have been inadequate to detect a significant difference in outcomes such as survival. Although the groups did not differ for survival at 1 year, the p value approached significance (p=0.07). Thus, the study might have had inadequate power to detect an actual survival difference between groups; such a difference could partly explain the excess rate of cerebral palsy in the dexamethasone group (ie, dexamethasone increased survival of infants who were at high risk of developing cerebral palsy). The dosing regimen used in this study may differ from that used in other NICUs and could possibly limit the generalisability of the findings. More infants in the dexamethasone group were exposed to antenatal steroids than in the placebo group (48% v 16%). It is unclear whether this difference may have played a role in the outcome of this study.
Despite its limitations, this study clearly raises concern about the long term effects of dexamethasone. The number needed to harm is 5, which indicates that if 5 infants receive this regimen of dexamethasone, 1 additional infant will develop cerebral palsy or neurological abnormality. Further randomised controlled trials are needed to examine the short and long term risks and benefits of dexamethasone with respect to lower doses, shorter courses, and timing of treatment initiation.
Source of funding for study by O'Shea et al: North Carolina Department of Environment, Health, and Natural Resources.
For correspondence:Dr TM O'Shea, Department of Pediatrics, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA. Fax +1 336 716 2525.
↵* Information provided by author.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.